Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 2/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29591350 | 1.00 | CD274 (0.39) | CD274CFDANO1PDE10AGAA | |
| SCHEMBL23218595 | 0.92 | DPP4 (0.39) | ANO1PDE10AGAAKDM4EPOLB | |
| SCHEMBL29852482 | 0.92 | DPP4 (0.39) | ANO1PDE10AGAAKDM4EPOLB | |
| SCHEMBL29591246 | 0.88 | CD274 (0.46) | CD274CFDANO1GAAKDM4E | |
| SCHEMBL23218362 | 0.88 | CD274 (0.46) | CD274CFDANO1GAAKDM4E | |
| SCHEMBL23218484 | 0.87 | CFD (0.40) | CD274CFDPDE10AKDM4EPOLB | |
| SCHEMBL29591505 | 0.87 | CFD (0.40) | CD274CFDPDE10AKDM4EPOLB | |
| SCHEMBL29591899 | 0.85 | CFD (0.39) | CD274CFDANO1GAAKDM4E | |
| SCHEMBL23218812 | 0.85 | CFD (0.39) | CD274CFDANO1GAAKDM4E | |
| SCHEMBL23218157 | 0.82 | CFD (0.38) | CD274CFDANO1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | CD274 2774/4885CFD 1/4885ANO1 2994/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | CD274 4001/4885CFD 1/4885ANO1 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.